| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b9890bf514086e8d1f302ec9e2fc0fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_64ea8d806c776597a7689704358496a1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6897 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6897
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 |
| filingDate |
1998-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2006-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d23eaff6fb357d3190750c83200c5ef7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa3e4ed8f46fe303cde582122d06ad95 |
| publicationDate |
2006-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0998936-B1 |
| titleOfInvention |
Substances for the prevention of pathological overexpression of TGF-Beta and methods for evaluating same |
| abstract |
The present invention is directed to use of an agent which is able to prevent pathological overexpression of TGF- beta gene in vivo for the preparation of a medicament for the treatment of disorders connected with AP-1 mediated TGF- beta gene expression, - except use of sulodexide, low molecular weight heparin derivatives obtained by chemical or enzymatic depolymerization, chemically modified heparin derivatives and low molecular weight dermatan sulfates obtained by chemical or enzymatic depolymerization for the treatment of diabetic nephropathy. Further, the invention provides convenient, fast in vitro methods to assess the value of agents useful for the said disorders. The disorder is further selected from disorders connected to excessive accumulation of extracellular matrix, disorders connected to inhibition of cell proliferation and disorders connected to immunomodulation and immunosuppression. <IMAGE> |
| priorityDate |
1998-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |